The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial ...

OCS-01 failed to meet the primary endpoint of improving visual acuity in both Phase 3 DIAMOND studies. ・The treatment reduced ...

An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation at Retina World ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular-mediated inflammation, today announced that the first ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular-mediated inflammation, today announced that the first ...

The durable medical equipment (DME) industry sits at a unique crossroads of healthcare delivery and supply chain logistics. Unlike standard medical billing, DME providers face a labyrinth of ...

As the Middle East crisis rattles global fuel markets, Indonesia needs to pull in more investments and technology transfers ...

Indonesia’s Energy Ministry said the country will continue developing its dimethyl ether, or DME, project as part of efforts ...

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

TAMPA, Fla. – ProCare, a privately held transportation and language services provider in the workers compensation industry, has launched a new durable medical equipment (DME) service line. The company ...

Phase 3 wet AMD trials, LUGANO and LUCIA, remain on track with topline data expected beginning mid-2026 –Phase 3 DME clinical trials, COMO and ...